Ipilimumab with and without Nivolumab in Patients with Classic Hodgkin Lymphoma with Progression after PD-1 Blockade

被引：0

作者：

Merryman, Reid W. ^{[1
]}

Kline, Justin ^{[2
]}

Redd, Robert A. ^{[3
]}

Welsh, Emma L. ^{[4
]}

Pfaff, Kathleen ^{[4
]}

Lee, Hannah Juhaie ^{[1
]}

Mcdonough, Mikaela M. ^{[5
]}

Ahn, Inhye E. ^{[1
]}

Brown, Jennifer R. ^{[6
]}

Crombie, Jennifer L. ^{[1
]}

Davids, Matthew S. ^{[1
]}

Fisher, David C. ^{[1
]}

Jacobsen, Eric D. ^{[7
]}

Jacobson, Caron A. ^{[1
]}

Kim, Austin I. ^{[1
,5
]}

Odejide, Oreofe O. ^{[1
]}

Parry, Erin M. ^{[1
]}

Ryan, Christine E. ^{[1
]}

Shipp, Margaret A. ^{[1
]}

Armand, Philippe ^{[1
]}

Rodig, Scott J. ^{[4
]}

Abramson, Jeremy S. ^{[8
]}

Lacasce, Ann S. ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA

[2] Univ Chicago Med, Dept Med, Sect Hematol Oncol, Chicago, IL USA

[3] Dana Farber Canc Inst, Dept Data Sci, Boston, MA USA

[4] Brigham & Womens Hosp, Dept Pathol, Boston, MA USA

[5] Dana Farber Canc Inst, Boston, MA USA

[6] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA

[7] Dana Farber Canc Inst, Boston, MA USA

[8] Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-203414

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1669 / 1670

页数：2

共 50 条

[21] Loss of nivolumab binding to T cell PD-1 predicts relapse of Hodgkin lymphoma
Ogasawara, Reiki
Hashimoto, Daigo
Sugita, Junichi
Yamawaki, Fumihiko
Naka, Tomoaki
Mitsuhashi, Tomoko
Takahashi, Shuichiro
Miyashita, Naohiro
Okada, Kohei
Onozawa, Masahiro
Matsuno, Yoshihiro
Teshima, Takanori
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 111 (03) : 475 - 479
[22] Loss of nivolumab binding to T cell PD-1 predicts relapse of Hodgkin lymphoma
Reiki Ogasawara
Daigo Hashimoto
Junichi Sugita
Fumihiko Yamawaki
Tomoaki Naka
Tomoko Mitsuhashi
Shuichiro Takahashi
Naohiro Miyashita
Kohei Okada
Masahiro Onozawa
Yoshihiro Matsuno
Takanori Teshima
International Journal of Hematology, 2020, 111 : 475 - 479
[23] Efficacy of Decitabine plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy
Wang, Chunmeng
Liu, Yang
Dong, Liang
Li, Xiang
Yang, Qingming
Brock, Malcolm, V
Mei, Qian
Liu, Jiejie
Chen, Meixia
Shi, Fengxia
Liu, Miao
Nie, Jing
Han, Weidong
CLINICAL CANCER RESEARCH, 2021, 27 (10) : 2782 - 2791
[24] Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade
Mei, Matthew
Chen, Lu
Godfrey, James
Song, Joo
Egelston, Colt
Puverel, Sandrine
Budde, Elizabeth
Armenian, Saro
Nikolaenko, Liana
Nwangwu, Mary
Guo, Weihua
Gao, Lei
Lee, Peter
Chen, Robert
Daniels, Shari
Kennedy, Neena
Peters, Lacolle
Zain, Jasmine
Rosen, Steven
Forman, Stephen
Popplewell, Leslie
Kwak, Larry
Herrera, Alex F.
BLOOD, 2023, 142 (16) : 1359 - 1370
[25] PD-1 Blockade with Pembrolizumab in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Safety, Efficacy, and Biomarker Assessment
Armand, Philippe
Shipp, Margaret A.
Ribrag, Vincent
Michot, Jean-Marie
Zinzani, Pier Luigi
Gutierrez, Martin
Snyder, Ellen
Ricart, Alejandro D.
Balakumaran, Arun
Moskowitz, Craig H.
BLOOD, 2015, 126 (23)
[26] PD-1 blockade with nivolumab in endemic Kaposi sarcoma
Delyon, J.
Bizot, A.
Battistella, M.
Madelaine, I.
Vercellino, L.
Lebbe, C.
ANNALS OF ONCOLOGY, 2018, 29 (04) : 1067 - 1069
[27] Implementing PD-1 antibodies in the treatment of patients with Hodgkin lymphoma
Engert, A.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 227 - 228
[28] Safety and Efficacy of Allogeneic Stem Cell Transplantation after PD-1 Blockade for Patients with Relapsed/Refractory Classical Hodgkin Lymphoma
Beynarovich, Anastasiya V.
Lepik, Kirill
Mikhailova, Nataliia
Kondakova, Elena
Zalaylov, Yuri
Borzenkova, Evgeniya
Babenko, Elena
Darskaya, Elena I.
Moiseev, Ivan S.
Zander, Axel
Afanasyev, Boris
BLOOD, 2019, 134
[29] PD-1 Blockade with Pembrolizumab in Relapsed Low Grade Non-Hodgkin Lymphoma
Ding, Wei
Laplant, Betsy
Witzig, Thomas E.
Johnston, Patrick B.
Colgan, Joseph P.
Rech, Karen L.
Leis, Jose F.
Feldman, Andrew L.
He, Rong
Nowakowski, Grzegorz S.
Asmus, Erik J.
Inwards, David J.
Porrata, Luis
Habermann, Thomas M.
Lin, Yi
Thanarajasingam, Gita
Bennani, Nabila Nora
Reeder, Craig B.
Northfelt, Donald
Palmer, Jeanne
Kapoor, Prashant
Viswanatha, David S.
Ansell, Stephen M.
BLOOD, 2017, 130
[30] Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy
Glutsch, Valerie
Graen, Franziska
Weber, Judith
Gesierich, Anja
Goebeler, Matthias
Schilling, Bastian
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7

← 1 2 3 4 5 →